Alzheimer's Treatment Advances: A Technical Overview for Healthcare Developers and Informed Families

Tags: #health #caregiving #neuroscience #healthtech Alzheimer's research has reached an inflection point. For the first time in decades, we're seeing disease-modifying treatments move from clinical trials into real-world care settings — and that shift has meaningful implications not just for patients and families, but for anyone building or integrating healthcare systems around home-based care. This article breaks down the mechanisms behind new Alzheimer's therapies, how they're being evaluated in Quebec, and how professional home care infrastructure actually plugs into these treatment pipelines. The Mechanism Shift: From Symptom Management to Pathology Targeting For most of Alzheimer's pharmacological history, medications like donepezil and memantine worked downstream — managing neurotransmitter levels to slow symptom expression. The new class of treatments works upstream, targeting the amyloid cascade hypothesis directly. Monoclonal Antibody Therapies Amyloid precursor protein (APP)